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SUMMARY
Systemic sclerosis (SSc)-related Raynaud’s phenomenon (RP) and digital ulcers (DU) can impair health-related 
quality of life (HRQoL). The aim of our study was to estimate HRQoL in SSc patients treated with two different 
intravenous (IV) iloprost (ILO) regimens and in patients not treated with IV ILO. 
96 consecutive SSc patients were enrolled in a pragmatic, prospective and non-randomized study, and divided 
into 3 groups: not requiring therapy with IV ILO (N=52), IV ILO once monthly (N=24) or IV ILO for 5 con-
secutive days every 3 months (N=20). Patients were followed up for three months. We assessed HRQoL using 
the generic preference-based questionnaire EQ-5D-5L. We conducted multiple regression analyses to estimate, 
in each treatment group, the mean general health (GH) and the mean utility index of the EQ-5D-5L, adjusting 
for possible confounders. 
The mean adjusted utility index and GH score, after three months’ follow-up, were not different in the three 
groups: IV ILO was able to make patients requiring IV ILO similar to those not requiring it. Moreover, there 
was no difference in this model between the two ILO regimens (1 day monthly vs 5 consecutive days every 3 
months).
The two different IV ILO regimens (the most appropriate regimen was decided according to patients’ characteris-
tics and needs) were able to stabilize HRQoL in RP secondary to SSc non-adequately controlled by oral therapy.
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n	 INTRODUCTION
Systemic sclerosis (SSc) is a multi-organ immune-mediated disease leading to 
skin and internal organ fibrosis (1). In these 
patients, Raynaud’s phenomenon (RP), dig-
ital ulcers (DU) and major internal organs 
involvement (e.g. lung) have an impact on 
function, work ability, social participation, 
body image dissatisfaction and the overall 
quality of life (2, 3). According to the re-
cently revised European League Against 
Rheumatism (EULAR) recommendations 
for SSc treatment, dihydropyridine-type 
calcium antagonists should be used as first 
line therapy for RP and PDE-5 inhibitors 
can also be considered. Intravenous (IV) 
prostanoids, in particularly iloprost (ILO), 
should be used after oral therapy has failed 
to control severe RP (4). Furthermore, IV 
ILO is indicated as effective in healing DU 
and it should be considered in their treat-
ment (4). Unfortunately, recommendations 
do not provide any indications about IV 
ILO dosage and regimen. A recent review 
of the literature and expert consensus pro-
vide practical suggestions about ILO us-
age in RP and DU in SSc patients (5). In 
the last decades, health-related quality of 
life (HRQoL) has been recognized as fun-
damental to evaluate disease course and 
therapy efficacy. The EuroQol-5 dimen-
sions-5 levels (EQ-5D-5L) questionnaire 
is one of the most widely used generic 
preference-based instruments to assess the 
whole HRQoL, and its use is validated in 
SSc (6-8). The aim of the present study is 
to evaluate HRQoL among SSc patients 
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treated with two different IV ILO regimens 
and those not treated with IV ILO.
n	 MATERIALS AND METHODS
Study design
Briefly, between October 2016 and April 
2017, all consecutive adult subjects with 
SSc fulfilling the 2013 EULAR classifica-
tion criteria (9) were recruited at the Divi-
sion of Rheumatology, ASST Pini-CTO 
in Milan, Italy as part of a 3-month ob-
servational, prospective, pragmatic, single 
centre and no-profit study that has previ-
ously been described in detail (10). The 
ethical committee approved this study and 
informed consent was obtained from all 
patients. This was a sub-study protocol in 
which HRQoL data collected during the 
study were examined (inclusion criteria: 
SSc patients aged 18 years or older refer-
ring to our rheumatology clinic between 
Autumn 2016 and Winter 2017; exclu-
sion criteria: overlap syndrome, amputa-
tion of the 3rd or 4th finger of the dominant 
hand, lack of informed consent). During a 
comprehensive baseline evaluation and a 
3-month follow-up period, data were col-
lected from medical history; diagnostic 
examinations and investigations were per-
formed as previously described (10). 
Population
Each patient was treated according to cur-
rent clinical practice and stratified in three 
main groups: SSc patients from the out-
patient clinic not requiring therapy with IV 
ILO (group A), SSc patients treated with 
IV ILO once monthly (group B), and SSc 
patients treated with IV ILO for 5 consecu-
tive days every 3 months (group C).  Group 
B and C were treated with IV ILO at the 
dosage of 0.5-2.0 ng/kg/min for 6 consecu-
tive hours. IV ILO therapy, according to 
EULAR recommendations (4) and good 
clinical practice, was administered only in 
patients with severe RP after oral therapy 
failure and in patients with DU. The regi-
men (group B vs group C) was chosen ac-
cording to demographic and clinical char-
acteristics, logistic aspects and patients’ 
preferences.
Health related quality of life assessment
The endpoint was to describe, measure and 
value HRQoL in patients treated with IV 
ILO administered with two different regi-
mens (group B and C) and in patients not 
treated with IV ILO (group A).
HRQoL was assessed using EQ-5D-5L, 
telephone interview version. A telephone 
appointment was made with each partici-
pant some days before the interview. Group 
A was interviewed at baseline and after 3 
months. Group B was interviewed at every 
monthly infusion and 15 days after that. 
Group C was interviewed before each infu-
sion cycle, and 15 and 45 days after the first 
infusion. Safety was assessed with adverse 
events, serious adverse events, discontinu-
ations due to adverse events, and labora-
tory observations.
EQ-5D-5L 
EQ-5D-5L is a preference-based generic 
instrument for the description, measure-
ment and valuation of health. The Italian 
version of the EQ-5D-5L has been used and 
tested for validation in some studies (11, 
12). It consists of two parts. The first one 
is a descriptive system including five do-
mains: mobility, self-care, usual activities, 
anxiety/depression and pain/discomfort. 
Each domain includes 5 severity levels: no 
problem, mild problems, moderate prob-
lems, severe problems and extreme prob-
lems. The second part of the questionnaire 
consists of a visual analogue scale (VAS) 
measuring the overall GH, ranging from 0 
(worst imaginable health state) to 100 (best 
imaginable health state). To calculate the 
utility index from the EQ-5D-5L descrip-
tive system, the responses in the descrip-
tive system were converted into utilities 
using the mapping algorithm developed by 
van Hout et al. and applied on the Italian 
social tariffs (13, 14).
Statistical analysis
Sociodemographic and clinical character-
istics of the study sample are described 
with proportions for categorical data, mean 
as the central tendency parameter for con-
tinuous data, and minimum and maximum 
values as dispersion parameters.
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We conducted multiple regression analyses 
to compare the mean GH (using the linear 
regression analysis) and the mean utility 
index (using the Tobit regression analysis) 
between the three treatment groups, ad-
justing for possible confounders: age, sex, 
treatment group, baseline utility or GH, 
average outdoor temperature during the 
week before the evaluation at the patient’s 
place of residence (data provided by Meteo 
Operations Italia (MOPI) Srl - Centro Ep-
son Meteo), RP VAS, disease duration and 
modified Rodnan skin score. 
In the regression analyses, P-values <0.05 
(two-tailed tests) were considered statisti-
cally significant and are reported with 95% 
confidence intervals. All analyses were 
conducted using Stata SE 12 (Stata Corp., 
College Station, TX, USA) software.
n	 RESULTS
Study population
Between Autumn 2016 and Winter 2017, a 
total of 109 SSc patients were enrolled in 
the study. 13 patients did not satisfy eligibil-
ity criteria and were then excluded. Among 
the 96 SSc patients included, 52 were not 
on ILO therapy (group A), 24 were treated 
with IV ILO once monthly (group B), and 
20 received IV ILO 5 days every 3 months 
(group C). Of these, for each group, respec-
tively, 35, 21 and 16 completed the study. 
In group A, 17 patients were evaluated after 
the time limit for study follow-up; in group 
B there were 3 drop-outs: 1 atrial fibrilla-
tion not correlated with IV ILO, 1 pneumo-
nia and 1 breast cancer relapse; in group C 
there were 4 drop-outs: 1 for IV ILO intol-
erance and 3 were evaluated after the time 
limit for study follow-up. Patients who did 
not complete the study were included in 
statistical analysis until their last follow-up 
in order to minimize distortion. The propor-
tion of patients who discontinued treatment 
was similar between the two treatments. 
Patients had a median age of 62.2 years, 
86.5% were female, 88.5% presented a 
cutaneous limited SSc, 97.9% were ANA 
positive (centromere pattern 51%), 38.5% 
were anti-Scl70 positive, 16.7% were active 
smokers and 30.2% (group A: 23%, B: 57%, 
C: 44%) had a history of one or more DU. 
At baseline no DU was observed and all pa-
tients had RP. Patients included in the study 
were treated with systemic corticosteroids 
(group A: 9%, B: 38%, C: 25%), calcium 
Figure 1 - Patients reporting moderate, severe or extreme problems, 
in every domain considered, for each treatment group (group A: no IV 
ILO, group B: IV ILO once monthly, group C: IV ILO for 5 consecutive 
days every 3 months).
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Ba
se
lin
e
15
 da
ys
1°
 m
on
th
45
 da
ys
2°
 m
on
th
75
 da
ys
3°
 m
on
th
GROUP A
Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depressi
on
0%
10%
20%
30%
40%
50%
60%
70%
80%
Ba
se
lin
e
15
 da
ys
1°
 m
on
th
45
 da
ys
2°
 m
on
th
75
 da
ys
3°
 m
on
th
GROUP B
Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depressi
on
0%
10%
20%
30%
40%
50%
60%
70%
Ba
se
lin
e
15
 da
ys
1°
 m
on
th
45
 da
ys
2°
 m
on
th
75
 da
ys
3°
 m
on
th
GROUP C
Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depressi
on
No
n-c
om
me
rci
al 
us
e o
nly
Reumatismo 2/2019 65
HRQoL in scleroderma treated with iloprost
ORIGINAL
PAPER
channel blockers (group A: 34%, B: 57%, 
C: 38%), peripheral vasodilators (group 
A: 23%, B: 33%, C: 44%), endothelin re-
ceptor antagonists (group A: 9%, B: 33%, 
C: 19%) and immunosuppressive therapy 
(group A: 14%, B: 24%, C: 25%). Detailed 
information on treatment and comorbidities 
is available in the supplementary materials 
of the original article (10).
EQ-5D-5L and general health
Percentages of patients who reported mod-
erate, severe or extreme problems for every 
domain considered are reported in Figure 
1 and Table I. In group A, the parameters 
considered were not different from base-
line; in group B, the parameters considered 
(particularly pain/discomfort) were at low-
est levels 15 days after IV ILO infusions; 
in group C, all the parameters considered 
decreased 15 days after the first cycle and 
tended to rise till the following one.
Moreover, we described the overall trend of 
GH for each group (Figure 2 and Table I). 
GH showed an increase, even if not statis-
tically significant, after each IV ILO infu-
Table I - EQ-5D-5L (percentages of patients reporting moderate, severe or extreme problems for each dimension considered) and 
general health (GH) for each treatment group (group A: no IV ILO, group B: IV ILO once monthly, group C: IV ILO for 5 consecutive 
days every 3 months).
Group A Baseline 15 days 1st month 45 days 2nd month 75 days 3rd month
Mobility 27% – – – – – 14.3%
Self-care 13.5% – – – – – 5.7%
Usual activities 19.2% – – – – – 22.9%
Pain/discomfort 40.4% – – – – – 40.0%
Anxiety/depression 26.9% – – – – – 40.0%
GH (VAS) ± sd 72.5±19 – – – – – 78.6±16.5
Group B
Mobility 8% 16.7% 27.3% 19.0% 33.3% 14.3% 33.3%
Self-care 12.5% 16.7% 22.7% 23.8% 19.0% 19.0% 23.8%
Usual activities 29.2% 29.2% 31.8% 28.6% 23.8% 33.3% 19.0%
Pain/discomfort 37.5% 37.5% 59.1% 42.9% 71.4% 42.9% 57.1%
Anxiety/depression 25.0% 8.3% 18.2% 19.0% 23.8% 14.3% 23.8%
GH (VAS) ± sd 64.8±19.2 73.9±17.3 67.7±18.8 73.1±18.1 64±18.4 65±21.6 66.7±19.3
Group C
Mobility 25% 14.3% – 18.8% – – 18.8%
Self-care 15.0% 21.4% – 37.5% – – 12.5%
Usual activities 30.0% 21.4% – 50.0% – – 25.0%
Pain/discomfort 60.0% 35.7% – 37.5% – – 37.5%
Anxiety/depression 50.0% 21.4% – 6.3% – – 12.5%
GH (VAS) ± sd 68±16.2 65.3±14.9 – 68.4±16.7 – – 75±14.6
GH, general health; VAS, visual analogue scale; sd, standard deviation. 
Figure 2 - General health, measured as visual analogue scale from 0 
to 100, for each treatment group (group A: no IV ILO, group B: IV ILO 
once monthly, group C: IV ILO for 5 consecutive days every 3 months).
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sion in group B. GH tended to build up 15 
days after IV ILO therapy for 5 consecutive 
days (group C).
The results of the regression models showed 
that GH and utility index were not different 
between the three different groups, adjust-
ing for the possible confounders consid-
ered, as shown from the P-values >0.5 and 
95% confidence intervals including the 0 
value (Table II).
n	 DISCUSSION
To our knowledge, this is the first study 
exploring HRQoL of SSc patients man-
aged with three different approaches ac-
cording to clinical practice: those who 
did not receive any IV ILO treatment, and 
those receiving IV ILO with two differ-
ent regimens, as a second line treatment to 
control RP or to obtain DU healing. Due 
to the lack of indications about IV ILO us-
age, the two regimens were administered 
considering nuanced criteria: demographic 
and clinical characteristics, logistic as-
pects and patients’ preferences. For these 
reasons, although a direct comparison be-
tween groups was not possible since allo-
cation was not randomly assigned, some 
considerations can be made. At the end of 
the study, both IV ILO regimens allowed 
to reach and to stabilize a similar HRQoL 
in the three groups. We reckon that the 
present study has some limitations such 
as small sample size, not fully elucidated 
psychometric properties of EQ-5D-5L and 
short follow-up.
Healthcare therapeutic interventions 
should include both evidence-based medi-
cine (EBM) and shared decision-making 
(SDM) approaches (15). Since a clearly su-
perior IV ILO regimen is currently not ade-
quately supported by EBM (5), we applied 
predominantly the SDM approach. The 
best regimen was chosen by both clinicians 
and patients considering patients’ prefer-
ences and circumstances. In this pragmatic 
study, patients were first stratified accord-
ing to RP severity and DU presence: IV 
ILO therapy was proposed only to patients 
not adequately controlled by oral therapy. 
In addition, IV ILO regimen was tailored 
based on the abovementioned approach. 
The choices we made about IV ILO regi-
men provide one example of how much 
further medicine could go in taking advan-
tage of a more nuanced understanding of 
the decision-making process. Since at the 
Table II - Regression model for utility index and general health (GH) at the end of the three months in the three patient groups.
Independent variable  
description
Utility index GH (VAS)
Coefficient P 95% CI Coefficient P 95% CI
Age (years) –0.001 0.149 –0.002 0.000 –0.332 0.026 –0.623 –0.041
Sex
Female (reference) – – – – – – – –
Male 0.028 0.148 –0.010 0.067 3.637 0.521 –7.618 14.891
Treatment group
ILO monthly (reference) – – – – – – – –
ILO for 5 days every 3 months 0.001 0.975 –0.037 0.038 7.252 0.182 –3.486 17.990
No ILO –0.005 0.771 –0.037 0.028 9.160 0.055 –0.185 18.505
Utility at baseline 0.731 0.000 0.526 0.936 0.270 0.012 0.061 0.478
Average temperature 0.003 0.155 –0.001 0.007 0.219 0.714 –0.971 1.409
RP VAS –0.005 0.054 –0.010 0.000 –1.114 0.131 –2.569 0.341
Disease duration 0.001 0.534 –0.001 0.002 0.172 0.510 –0.348 0.693
Skin score (mRSS) –0.003 0.021 –0.006 –0.001 –0.161 0.695 –0.977 0.655
Constant 0.241 0.025 0.032 0.451 68.969 0.000 37.504 100.43
ILO, iloprost; VAS, visual analogue scale; CI, coefficient interval; RP, Raynaud’s phenomenon; mRSS, modified Rodnan skin score. 
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end of the study patients showed compara-
ble levels of HRQoL independently from 
the IV ILO regimen, the SDM process 
seems reasonable in choosing the best IV 
ILO therapy for each patient. Further stud-
ies are required to assess definitively the 
best IV ILO regimen in patients with SSc.
n	 CONCLUSIONS
According to EULAR recommendations, 
prostacyclin IV therapy should be consid-
ered in patients with RP or DU secondary 
to SSc not adequately treated by oral ther-
apy. In our cohort, SSc patients with DU 
history were mainly treated with IV ILO. 
Patients treated with the two different IV 
ILO regimens (1 monthly vs 5 consecutive 
days every 3 months) did not show any sta-
tistically significant difference with respect 
to HRQoL. 
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